|About us | Services | Products | News | Careers | Contact us|
12/30/2012: Happy new year! In year of 2012, we had a wonderful year. Many thanks to all of our clients, partners, and employees. During 2012, MedKoo with its partners have successfully made over 20 very challenge target molecules: including Oprozomib; PF-03758309; Pelitrexol; ARRY-520; SGI-110; Varlitinib; UNC-0638; GSK-2636771; Talampanel; Semapimod, Carfilzomib; ACY-1215; TG-02; ABC294640; Golvatinib; AT-13387; Baricitinib; Cobicistat; etc.
05/30/2012: Gemcitabine elaidate (CO-101, CP-4126) available for research
MedKoo announced today, Gemcitabine elaidate (CO-101, CP-4126) is available for research. CO-101 is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, CO-101 exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase. For price please click the link Gemcitabine elaidate (CO-101, CP-4126)
02/17/2012: Ganetespib available for research
MedKoo announced today, Ganetespib (STA-9090) is available fro research. Ganetespib is a Hsp90 inhibitor, currently being by Synta Pharmaceuticals. Ganetespib (STA-9090) has shown potency up to 100 times greater than the first-generation Hsp90 inhibitors as well as activity against a wider range of kinases. In in vitro and in vivo models, Ganetespib (STA-9090) has shown potent activity against a wide range of cancer types, including lung, prostate, colon, breast, gastric, pancreatic, melanoma and certain hematologic cancers - as well as potent activity against cancers resistant to Gleevec, Sutent, Tarceva, Sprycel, and 17-AAG. For pricing, please clinical Ganetespib (STA-9090) to see the detail.
01/23/2012: PX-478 available for research.
MedKoo announced today that PX-478 is available for research. PX-478 is a highly water soluble molecule, with good i.v., i.p. and p.o. antitumor activity. It is rapidly absorbed following oral and i.p. administration and gives excellent Cmax and AUC via these routes. For pricing, please click PX-478 to see the detail.
01/03/2012: Anticancer drug candidates in preclinical study added
MedKoo Biosciences added a new collection of products: anticancer small molecule agents in pre-clinical studies. This page will be updated on weekly basis. Please click the link to see the detail
06/01/2011: Talaporfin sodium available with high qualtiy
Chapel Hill, North Carolina, USA. MedKoo Biosciences is pleased to announce the success of developing a scalable process to make talaporfin sodium with high purity. Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorine e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT). It absorbs red light at 664nm normally provided by a laser tuned to this wavelength. It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin. Please click the link for talaporfin sodium for detail.
(Keyword; CAS#; MedKoo code#)
About us | Services | Products | News | Careers | Contact us